Chronic Lymphocytic Leukemia

In the treatment paradigm of chronic lymphocytic leukemia, anti-CD20 antibodies such as obinutuzumab, and other targeted agents like ibrutinib, have shown promising efficacy and tolerability when compared with standard chemoimmunotherapy.

Andrew D. Zelenetz, MD, PhD, medical director of Quality Informatics at Memorial Sloan Kettering Cancer Center, discusses treatment options for patients with chronic lymphocytic leukemia who fail on ibrutinib or idelalisib.

Novel therapies are being investigated in 2 areas of hematologic malignancies, but the first-line setting is where the brunt of research needs to be conducted.

Jeffrey Jones, MD, MPH, assistant professor of Internal Medicine, Division of Hematology, The Ohio State University, discusses the results of a phase II study that evaluated the efficacy of venetoclax in the treatment of patients with chronic lymphocytic leukemia whose disease had progressed after treatment with either ibrutinib or idelalisib.

The European Commission has approved ofatumumab in combination with fludarabine and cyclophosphamide as a treatment for adult patients with relapsed chronic lymphocytic leukemia.

Two thirds of patients with chronic lymphocytic leukemia (CLL) that progressed on B-cell receptor pathway inhibitors had objective responses to treatment with venetoclax, results of a small open-label trial showed.

Jennifer Woyach, MD, associate professor, Ohio State University, discusses a study examining the use of MOR208 combined with lenalidomide (Revlimid) for the treatment of chronic lymphotic leukemia (CLL) during the American Society of Hematology (ASH) Annual Meeting.

Treatment with the BTK inhibitor BGB-3111 had an objective response rate of 96% for patients with chronic lymphocytic leukemia and small lymphocytic leukemia.

The investigational Bruton tyrosine kinase inhibitor acalabrutinib was shown to be well-tolerated in patients with chronic lymphocytic leukemia and small lymphocytic leukemia who display intolerance to ibrutinib (Imbruvica).

The combination of the PI3 kinase inhibitor TGR-1202 and ibrutinib demonstrated a high response rate without dose-limiting toxicities for patients with relapsed/refractory chronic lymphocytic leukemia and mantle cell lymphoma.

Ibrutinib showed an 89% response rate in both treatment-naïve and relapsed patients with chronic lymphocytic leukemia/small lymphocytic lymphoma in findings from the longest follow-up to date for the BTK inhibitor.

Lenalidomide as maintenance following first-line immunochemotherapy substantially improves progression-free survival in the treatment of patients with high-risk chronic lymphocytic leukemia.

Constantine Tam, MD, discusses 2 trials investigating BTK inhibitor BGB-3111 in chronic lymphocytic leukemia (CLL) and Waldenstrom’s macroglobulinemia.

The next-generation BTK inhibitor acalabrutinib produced an objective response rate of 38.1% as a monotherapy for patents with Richter transformation.

Treatment with the combination of nivolumab and ibrutinib showed encouraging activity and safety in a small phase II study of patients with chronic lymphocytic leukemia and Richter transformation.

William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses factors that physicians should take into account when administering frontline treatment options to patients with chronic lymphocytic leukemia.

As with software upgrades, Carl H. June, MD, sees his work in cancer research as a job with ever-evolving updates.

Standard treatment approaches for patients with chronic lymphocytic leukemia will continue to include fludarabine, cyclophosphamide, and rituximab and allogeneic stem cell transplantation.

The Committee for Medicinal Products for Human Use has recommended approval of ofatumumab in combination with fludarabine and cyclophosphamide as a treatment for patients with relapsed chronic lymphocytic leukemia.

Jennifer R. Brown, MD, PhD, Director, CLL Center, Dana-Farber Cancer Institute, associate professor of Medicine, Harvard Medical School, discusses the recent progress seen in the treatment landscape of chronic lymphocytic leukemia (CLL), and what still needs to be accomplished going forward.

Alessandra Ferrajoli, MD, a professor of Medicine in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, discusses the challenges that still remain in patients with chronic lymphocytic leukemia.

William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses the management of patients with chronic lymphocytic leukemia (CLL) in the firstline setting.

As more agents are approved in the treatment paradigm of chronic lymphocytic leukemia, researchers are exploring frontline options—in addition to ibrutinib and the regimen of fludarabine, cyclophosphamide, and rituximab—in ongoing trials.

Jose Leis, MD, associate professor of Medicine, Mayo Clinic, discusses treatment-related advances in the field of chronic lymphocytic leukemia (CLL) over the last several decades in an interview during the 2016 OncLive State of the Science Summit on Hematologic Malignancies.

Patients with chronic lymphocytic leukemia have an increased likelihood of developing secondary cancers and other diseases, often based on their age and gender.

Jan A. Burger, MD, PhD, associate professor, department of leukemia, division of cancer medicine, The University of Texas MD Anderson Cancer Center, discusses the role of minimal residual disease (MRD)-negativity in chronic lymphocytic leukemia (CLL).

The Committee for Medicinal Products for Human Use has recommended approval of venetoclax for the treatment of patients with chronic lymphocytic leukemia who have a 17p deletion (del[17p]) or TP53 mutation and are not good candidates for or have failed on a B-cell receptor pathway inhibitor. The potential indication would also be for patients who do not harbor the deletion or mutation but have progressed on both a BCR inhibitor and chemoimmunotherapy.

William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discuses which chronic lymphocytic leukemia patients may benefit from ibrutinib frontline therapy and questions that remain after the RESONATE-2 trial.